Bioventus Reports First Quarter Financial Results
Bioventus delivered a strong start to 2026 with Q1 revenue of $132.1 million, up 7% year-over-year, and GAAP EPS of $0.04 compared to a prior-year loss. Cash generation improved significantly, with cash from operations reaching $8.9 million, a $28.3 million increase from the prior-year period, enabling a $22 million discretionary debt prepayment.
Key figures
- Eps
- 0.04
- Revenue
- 132100000
- Guidance
- FY26 Adj. EPS $0.75-$0.79, Cash from Ops $84M-$89M, Revenue $600M-$610M
- Revenue Yoy
- 7%
- Net income
- 3100000
- Non gaap eps
- 0.15
- Adjusted ebitda
- 23900000
- Cash from operations
- 8900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.